Metavectum has analysed four tumour resectates which we got from Prof.
Jacobi, Wesseling.
As already mentioned in previous reports, tumor stem cells
(CD133/CD44/MET) are the dominant species in all samples. The amount of
tumor stem cells has increased once again, not least because of inadequate
treatment. A combined therapy is recommended:
1) Cabozantinib/Cometriq or possibly Crizotinib plus Cetuximab.
2) The Expression of PSMA is strongly elevated. This gives another
possibility for treatment. The following procedure might be useful:
a) PSMA-PET-CT Scan (z.B. Prof. Ruhlmann Bonn).
b) Removal of the PSMA-positive metastases using Cyberknife
c) Instead of Cyberknife use PSMA-177Lu.
PSMA-177Lu is an antibody (PSMA) coupled to the radioactive Isotope 177Lu.
The PSMA-177Lu migrates only to PSMA active tumours/metastases and destroy
them.
If you have further questions don’t hesitate to contact me.
I MADE THE DRIVE TO FRANKFURT
MY TARGET STEM CELLS
NOW I HAVE A CHANCE